All In Biotech

Drug Trial Radar · NCT06598735

A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors

An Open, Multicenter Phase I Study of Safety, Tolerability, and Pharmacokinetics of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Nov 5, 2024

Primary completion

Dec 30, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of HRS-4508 in subjects with advanced or metastatic solid tumors and explore the reasonable dosage of HRS-4508.

Conditions

  • Advanced Solid Tumors

Interventions

  • HRS-4508Drug

    HRS-4508

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoints: Number of subjects with adverse events and the severity of adverse eventsTime frame: every 4 weeks after treatment initiation (through study completion, an average 5 mouths)
  2. DLT (Dose-limiting toxicity)Time frame: during the first 21-day cycle of HRS-4508 treatment
  3. MTD (Maximum tolerated dose)Time frame: 3 weeks after treatment initiation
  4. RP2D (Recommended Phase II Dose)Time frame: 3 weeks after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.